
MMJ BioPharma Cultivation, a cannabis company, received its DEA schedule 1 Analytical Lab Registration, which allows for the international importation of cannabis for research and development.
In addition, MMJ BioPharma has been awarded FDA “Orphan Designation” for its clinical trial in Huntington’s Disease. The company also has an investigational new drug (IND) application filed with the FDA to begin clinical trials in Multiple Sclerosis. Meanwhile, MMJ is awaiting the DEA to issue its bulk manufacturing registration.